Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.
University of Ottawa, Ottawa, Canada.
Cancer Treat Res Commun. 2022;32:100570. doi: 10.1016/j.ctarc.2022.100570. Epub 2022 Apr 30.
Mucinous adenocarcinoma is a rare subtype of lung cancer characterized by abnormal mucin production. We sought to investigate the clinical and pathological features of pulmonary mucinous adenocarcinomas and to identify prognostic factors.
This was a single-institution retrospective review of patients with pulmonary mucinous adenocarcinoma diagnosed between January 1, 2015 and December 31, 2020. Descriptive analysis included demographics, diagnostic data, and treatment modalities. The primary outcome was overall survival (OS).
Fifty-six patients were included in the study. Median age was 65 years (range: 26-84), 30 (54%) were female, 48 (86%) had a smoking history, and 41 (73%) patients had ECOG performance status 0-1. Nearly half (26, 46%) were stage IV at presentation, while 11 (20%) presented as stage I, 10 (18%) stage II, and 9 (16%) stage III. Biomarker testing increased through the study period. Where performed, 4/48 (8%) cases were ALK positive, but there were no EGFR cases identified (0/36). Only 3/20 cases had PD-L1 expression >50%. Curative intent therapy was performed in 23 patients (17 had surgery +/- chemotherapy/radiation, 4 had radiotherapy alone, 2 had chemoradiation). Median OS in the entire population was 16.1 months (m). OS by stage was 50.0m for stage I, not reached for stage II, 20.7m for stage III, and 8.1m for stage IV.
The overall prognosis of pulmonary mucinous adenocarcinoma appears similar to that of non-mucinous adenocarcinomas, with distinct differences noted in the incidence of oncogenic driver mutations, particularly an absence of EGFR mutations.
黏液性腺癌是一种罕见的肺癌亚型，其特征是异常的黏蛋白产生。我们旨在研究肺黏液性腺癌的临床和病理特征，并确定预后因素。
这是一项对 2015 年 1 月 1 日至 2020 年 12 月 31 日期间诊断为肺黏液性腺癌的患者进行的单机构回顾性研究。描述性分析包括人口统计学、诊断数据和治疗方式。主要结果是总生存期（OS）。
本研究共纳入 56 例患者。中位年龄为 65 岁（范围：26-84 岁），30 例（54%）为女性，48 例（86%）有吸烟史，41 例（73%）患者的 ECOG 表现状态为 0-1。近一半（26 例，46%）患者在就诊时为 IV 期，11 例（20%）为 I 期，10 例（18%）为 II 期，9 例（16%）为 III 期。生物标志物检测在研究期间有所增加。在进行检测的 48 例患者中，4 例（8%）ALK 阳性，但未发现 EGFR 病例（36 例均为阴性）。仅有 3 例（20%）患者的 PD-L1 表达>50%。23 例患者（17 例接受手术+/-化疗/放疗，4 例接受单纯放疗，2 例接受放化疗）接受了根治性治疗。全人群的中位 OS 为 16.1 个月（m）。各期的 OS 分别为 I 期 50.0m，II 期未达到，III 期 20.7m，IV 期 8.1m。
肺黏液性腺癌的总体预后似乎与非黏液性腺癌相似，但在致癌驱动基因突变的发生率方面存在明显差异，特别是 EGFR 突变缺失。
